6-K: Voting Rights and Capital
6-K: Dato-DXd NSQ NSCLC Application Withdrawn in EU
6-K: Tagrisso Approved in EU Based on LAURA Trial
6-K: Rene Haas and Birgit Conix Have Been Appointed as Non-Executive Directors
6-K: Imfinzi Approved in Us for Limited-Stage SCLC
6-K: AstraZeneca Appoints Iskra Reic EVP International
6-K: Block Listing Six Monthly Return
6-K: Voting Rights and Capital
6-K: Truqap Improved rPFS in Advanced Prostate Cancer
6-K: Transaction by Person Discharging Managerial Responsibilities
6-K: Tagrisso Recommended for EU Approval
6-K: Transaction by Person Discharging Managerial Responsibilities
6-K: Director/PDMR Shareholding
6-K: Transaction by Person Discharging Managerial Responsibilities
6-K: 9M and Q3 2024 Results
6-K: Dato-DXd New BLA Submitted, NSQ BLA Withdrawn
6-K: KOMET Phase III Trial Met Primary Endpoint
6-K: AstraZeneca Invests $3.5 Billion in US
6-K: Tezspire Met Both Co-Primary Endpoints in the Phase III WAYPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps
6-K: Voting Rights and Capital